CoChat
Sign Up
Cited by 522

A regenerative approach to the treatment of multiple sclerosis

Deshmukh, Vishal A., Tardif, Virginie, Lyssiotis, Costas A., Green, Chelsea C., Kerman, Bilal, Kim, Hyung Joon, Padmanabhan, Krishnan, Swoboda, Jonathan G. +7 more·2013·Nature
DOI 10.1038/nature12647PMC PMC4431622
Open this paper in CoChat — free account

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/nature12647

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Functional recovery in MS patients will likely hinge on therapies that promote myelin regeneration.

    “Functional recovery in MS patients will likely hinge on the therapies that promote myelin regeneration (Deshmukh et al., 2013; Franklin and Gallo, 2014).”

    From miR-219 Cooperates with miR-338 in Myelination and Promotes Myelin Repair in the CNS (2017) · cites this paper as Deshmukh et al., 2013

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 51

  1. [1]Franklin RJ Ffrench-Constant C Remyelination in the CNS: from biology to therapy Nature Rev. Neurosci 2008 9 839 855 18931697
  2. [2]Franklin RJ Why does remyelination fail in multiple sclerosis? Nature Rev. Neurosci 2002 3 705 714 12209119
  3. [3]Nunes MC Identification and isolation of multipotential neural progenitor cells from the subcortical white matter of the adult human brain Nature Med 2003 9 439 447 12627226
  4. [4]Belachew S Postnatal NG2 proteoglycan-expressing progenitor cells are intrinsically multipotent and generate functional neurons J. Cell Biol 2003 161 169 186 12682089 PMC2172886
  5. [5]Huang JK Retinoid X receptor gamma signaling accelerates CNS remyelination Nature Neurosci 2011 14 45 53 21131950 PMC4013508
  6. [7]Horner PJ Proliferation and differentiation of progenitor cells throughout the intact adult rat spinal cord J. Neurosci 2000 20 2218 2228 10704497 PMC6772504
  7. [8]Kremer D Aktas O Hartung HP Kury P The complex world of oligodendroglial differentiation inhibitors Ann. Neurol 2011 69 602 618 21520230
  8. [9]Patel JR Klein RS Mediators of oligodendrocyte differentiation during remyelination FEBS Lett 2011 585 3730 3737 21539842 PMC3158966
  9. [10]Chang A Tourtellotte WW Rudick R Trapp BD Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis N. Engl. J. Med 2002 346 165 173 11796850
  10. [11]Chari DM Huang WL Blakemore WF Dysfunctional oligodendrocyte progenitor cell (OPC) populations may inhibit repopulation of OPC depleted tissue J. Neurosci. Res 2003 73 787 793 12949904
  11. [12]Wolswijk G Chronic stage multiple sclerosis lesions contain a relatively quiescent population of oligodendrocyte precursor cells J. Neurosci 1998 18 601 609 9425002 PMC6792542
  12. [13]Kuhlmann T Differentiation block of oligodendroglial progenitor cells as a cause for remyelination failure in chronic multiple sclerosis Brain 2008 131 1749 1758 18515322
  13. [14]Hart IK Richardson WD Bolsover SR Raff MC PDGF and intracellular signaling in the timing of oligodendrocyte differentiation J. Cell Biol 1989 109 3411 3417 2557355 PMC2115923
  14. [15]Billon N Tokumoto Y Forrest D Raff M Role of thyroid hormone receptors in timing oligodendrocyte differentiation Dev. Biol 2001 235 110 120 11412031
  15. [16]Tokumoto YM Tang DG Raff MC Two molecularly distinct intracellular pathways to oligodendrocyte differentiation: role of a p53 family protein EMBO J 2001 20 5261 5268 11566889 PMC125631
  16. [17]Fernandez M Thyroid hormone administration enhances remyelination in chronic demyelinating inflammatory disease Proc. Natl Acad. Sci. USA 2004 101 16363 16368 15534218 PMC526198
  17. [18]Calzà L Fernandez M Giardino L Cellular approaches to central nervous system remyelination stimulation: thyroid hormone to promote myelin repair via endogenous stem and precursor cells J. Mol. Endocrinol 2010 44 13 23 19578096
  18. [19]Barres BA Lazar MA Raff MC A novel role for thyroid hormone, glucocorticoids and retinoic acid in timing oligodendrocyte development Development 1994 120 1097 1108 8026323
  19. [20]Buckley CE Drug reprofiling using zebrafish identifies novel compounds with potential pro-myelination effects Neuropharmacology 2010 59 149 159 20450924
  20. [21]Ibanez C Steroids and the reversal of age-associated changes in myelination and remyelination Prog. Neurobiol 2003 71 49 56 14611867
  21. [23]Joubert L Chemical inducers and transcriptional markers of oligodendrocyte differentiation J. Neurosci. Res 2010 88 2546 2557 20544820
  22. [24]Gard AL Pfeiffer SE Two proliferative stages of the oligodendrocyte lineage (A2B5+O4− and O4+GalC−) under different mitogenic control Neuron 1990 5 615 625 2223090
  23. [25]Pfeiffer SE Warrington AE Bansal R The oligodendrocyte and its many cellular processes Trends Cell Biol 1993 3 191 197 14731493
  24. [26]Gaspard N Generation of cortical neurons from mouse embryonic stem cells Nature Protocols 2009 4 1454 1463 19798080
  25. [27]Barres BA Cell death and control of cell survival in the oligodendrocyte lineage Cell 1992 70 31 46 1623522
  26. [28]Eshleman AJ Henningsen RA Neve KA Janowsky A Release of dopamine via the human transporter Mol. Pharmacol 1994 45 312 316 7906856
  27. [29]McKearney JW Stimulant actions of histamine H1 antagonists on operant behavior in the squirrel monkey Psychopharmacol 1982 77 156 158 6126904
  28. [30]Agoston GE Novel N-substituted 3α-[bis(4′-fluorophenyl)methoxy]tropane analogues: selective ligands for the dopamine transporter J. Med. Chem 1997 40 4329 4339 9435902
  29. [31]De Angelis F Bernardo A Magnaghi V Minghetti L Tata AM Muscarinic receptor subtypes as potential targets to modulate oligodendrocyte progenitor survival, proliferation and differentiation Dev. Neurobiol 2012 72 713 728 21913336
  30. [32]Stidworthy MF Notch1 and Jagged1 are expressed after CNS demyelination, but are not a major rate-determining factor during remyelination Brain 2004 127 1928 1941 15289265
  31. [33]Taveggia C Feltri ML Wrabetz L Signals to promote myelin formation and repair Nature Rev. Neurol 2010 6 276 287 20404842 PMC3062363
  32. [34]Ragheb F Pharmacological and functional characterization of muscarinic receptor subtypes in developing oligodendrocytes J. Neurochem 2001 77 1396 1406 11389190
  33. [35]Felder CC Muscarinic acetylcholine receptors: signal transduction through multiple effectors FASEB J 1995 9 619 625 7768353
  34. [36]Owens T Sriram S The immunology of multiple sclerosis and its animal model, experimental allergic encephalomyelitis Neurol. Clin 1995 13 51 73 7739505
  35. [37]Lawson BR Inhibition of transmethylation down-regulates CD4 T cell activation and curtails development of autoimmunity in a model system J. Immunol 2007 178 5366 5374 17404322
  36. [38]Mix E Meyer-Rienecker H Zettl UK Animal models of multiple sclerosis for the development and validation of novel therapies—potential and limitations J. Neurol 2008 255 Suppl 6 7 14 19300954
  37. [39]Steinman L Zamvil SS Virtues and pitfalls of EAE for the development of therapies for multiple sclerosis Trends Immunol 2005 26 565 571 16153891
  38. [40]Aharoni R Distinct pathological patterns in relapsing-remitting and chronic models of experimental autoimmune enchephalomyelitis and the neuroprotective effect of glatiramer acetate J. Autoimmun 2011 37 228 241 21752599
  39. [41]Liu L Myelin repair is accelerated by inactivating CXCR2 on nonhematopoietic cells J. Neurosci 2010 30 9074 9083 20610741 PMC2917803
  40. [42]Mi S LINGO-1 antagonist promotes spinal cord remyelination and axonal integrity in MOG-induced experimental autoimmune encephalomyelitis Nature Med 2007 13 1228 1233 17906634
  41. [43]Kawashima K Fujii T Basic and clinical aspects of non-neuronal acetylcholine: overview of non-neuronal cholinergic systems and their biological significance J. Pharmacol. Sci 2008 106 167 173 18285657
  42. [44]Stern JN Promoting tolerance to proteolipid protein-induced experimental autoimmune encephalomyelitis through targeting dendritic cells Proc. Natl Acad. Sci. USA 2010 107 17280 17285 20855626 PMC2951396
  43. [45]Steelman AJ Thompson JP Li J Demyelination and remyelination in anatomically distinct regions of the corpus callosum following cuprizone intoxication Neurosci. Res 2012 72 32 42 22015947 PMC3230728
  44. [47]Kappos L Oral fingolimod (FTY720) for relapsing multiple sclerosis N. Engl. J. Med 2006 355 1124 1140 16971719
  45. [48]Durelli L Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN) Lancet 2002 359 1453 1460 11988242
  46. [49]Noronha A Toscas A Jensen MA Interferon β decreases T cell activation and interferon γ production in multiple sclerosis J. Neuroimmunol 1993 46 145 153 8360326
  47. [50]Brinkmann V The immune modulator FTY720 targets sphingosine 1-phosphate receptors J. Biol. Chem 2002 277 21453 21457 11967257
  48. [51]Kondo T Raff M The Id4 HLH protein and the timing of oligodendrocyte differentiation EMBO J 2000 19 1998 2007 10790366 PMC305683
  49. [52]Wang S Sdrulla A Johnson JE Yokota Y Barres BA A role for the helix-loop-helix protein Id2 in the control of oligodendrocyte development Neuron 2001 29 603 614 11301021
  50. [53]Pang Y Neuron-oligodendrocyte myelination co-culture derived from embryonic rat spinal cord and cerebral cortex Brain Behav 2012 2 53 67 22574274 PMC3343299
  51. [54]Izrael M Human oligodendrocytes derived from embryonic stem cells: Effect of noggin on phenotypic differentiation in vitro and on myelination in vivo Mol. Cell. Neurosci 2007 34 310 323 17196394

Cited by

Sorted by citations

Authors
Deshmukh, V. A., Tardif, V., Lyssiotis, C. A., Green, C. C., Kerman, B., Kim, H. J., Padmanabhan, K., Swoboda, J. G., Ahmad, I., Kondo, T., Gage, F. H., Theofilopoulos, A. N., Lawson, B. R., Schultz, P. G., & Lairson, L. L.
Venue
Nature
Publisher
Springer Science and Business Media LLC
Published
2013-10-09
Volume
502
Issue
7471
Pages
327-332
ISSN
  • 0028-0836
  • 1476-4687
DOI
10.1038/nature12647
PMC
PMC4431622
Cited by
522
References
3
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review